BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, December 31, 2024
Breaking News: Holiday special – 25% off BioWorld subscriptions
See today's BioWorld Science
Home
» UP Oncolytics’ oncolytic virus-based therapy awarded US orphan drug designation to treat malignant glioma
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cancer
UP Oncolytics’ oncolytic virus-based therapy awarded US orphan drug designation to treat malignant glioma
Oct. 24, 2024
No Comments
The FDA has awarded orphan drug designation to UP Oncolytics LLC’s oncolytic virus-based therapy (ZIKV-SJRP/2016) to treat malignant glioma.
BioWorld Science
Regulatory
Cancer
FDA
Orphan drug
